Crystal Adam sold $604K of TNGX

Caleres Inc (CAL) reported Q2 earnings of $0.47 per share, beating estimates of $0.37, and raised FY26 EPS guidance. Shares rose 14.4% to $13.76. Other companies like Opus Genetics (IRD), Signet Jewelers (SIG), and Flotek Industries (FTK) also saw significant gains due to positive updates.

Tangram Therapeutics announced its MASH treatment TGM-312 has progressed to patient cohorts in a Phase 1/2 trial. The company also appointed Dr. Sonya Montgomery as Chief Development Officer. TGM-312 targets liver inflammation and steatosis, with interim data expected in 2027. Dr. Montgomery brings 25 years of experience in clinical development.

Tango Therapeutics (TNGX) shares fell about 4% to $26.58 after Q2 2026 results missed expectations. Net loss widened to $0.37 per share versus $0.35 a year earlier, above the ~$0.32 consensus. The quarter again had zero revenue. General and administrative expenses nearly doubled to $22.6M from $11.3M, driven by personnel and share-based comp.

Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 da

Canaccord Genuity raised its price target for Tango Therapeutics (NASDAQ:TNGX) to $46 from $42 and kept a Buy rating, citing a revised model that includes combined revenues from vopimetostat plus KRAS inhibitors in NSCLC. Jefferies upgraded TNGX to Buy and lifted its target to $60. Tango also signed an underwriting for about 18.2M shares plus pre-funded warrants, expecting ~$566.5M net proceeds for trials and R&D.

Biotech stocks rose Monday as investors reacted to clinical and regulatory updates. Tango Therapeutics (TNGX) jumped 52.97% after initial Phase 1/2 pancreatic cancer data showed 90% 6-month PFS; Alvotech (ALVO) gained 19.77% as the FDA accepted its Entyvio interchangeable biosimilar AVT16; Zevra (ZVRA) rose 13.95% on an Orange Book listing for MIPLYFFA.